Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonella Castagna

Showing results (211-220 of 467) with videos related to

Pageof 47
Sort By:
The Journal of Antimicrobial Chemotherapy|August 9, 2007
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairmentElena Seminari, Anna De Bona, Gianluca Gentilini, et al.
Journal of the International AIDS Society|August 2, 2015
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapyNicola Gianotti, Andrea Poli, Silvia Nozza, et al.
AIDS (London, England)|June 29, 2012
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimensAlba Bigoloni, Nicola Gianotti, Vincenzo Spagnuolo, et al.
Pathogens (Basel, Switzerland)|September 28, 2023
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, ItalyFlavia Passini, Angelo Roberto Raccagni, Sara Diotallevi, et al.
AIDS and Behavior|October 4, 2023
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in ItalyAngelo Roberto Raccagni, Laura Galli, Maria Francesca Lucente, et al.
BMC Health Services Research|February 17, 2012
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysisEnrico Girardi, Paola Scognamiglio, Claudio Angeletti, et al.
Pathogens and Global Health|March 7, 2022
Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in ItalyGiuseppina Brancaccio, Milensu Shanyinde, Massimo Puoti, et al.
Journal of Medical Virology|July 10, 2019
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimensNicola Gianotti, Camilla Muccini, Laura Galli, et al.
BMJ Open|January 5, 2023
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohortSilvia Nozza, Angelo Roberto Raccagni, Riccardo Lolatto, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trialFrancesca Lombardi, Simone Belmonti, Eugenia Quiros-Roldan, et al.
Pageof 47

Showing results (211-220 of 467) with videos related to

Sort By:
Pageof 47
The Journal of Antimicrobial Chemotherapy|August 9, 2007
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairmentElena Seminari, Anna De Bona, Gianluca Gentilini, et al.
Journal of the International AIDS Society|August 2, 2015
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapyNicola Gianotti, Andrea Poli, Silvia Nozza, et al.
AIDS (London, England)|June 29, 2012
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimensAlba Bigoloni, Nicola Gianotti, Vincenzo Spagnuolo, et al.
Pathogens (Basel, Switzerland)|September 28, 2023
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, ItalyFlavia Passini, Angelo Roberto Raccagni, Sara Diotallevi, et al.
AIDS and Behavior|October 4, 2023
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in ItalyAngelo Roberto Raccagni, Laura Galli, Maria Francesca Lucente, et al.
BMC Health Services Research|February 17, 2012
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysisEnrico Girardi, Paola Scognamiglio, Claudio Angeletti, et al.
Pathogens and Global Health|March 7, 2022
Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in ItalyGiuseppina Brancaccio, Milensu Shanyinde, Massimo Puoti, et al.
Journal of Medical Virology|July 10, 2019
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimensNicola Gianotti, Camilla Muccini, Laura Galli, et al.
BMJ Open|January 5, 2023
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohortSilvia Nozza, Angelo Roberto Raccagni, Riccardo Lolatto, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trialFrancesca Lombardi, Simone Belmonti, Eugenia Quiros-Roldan, et al.
Pageof 47